

October 31, 2023

The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Madam/Sir,

Sub.: Application for in-principle approval to Scheme of Arrangement amongst Strides Pharma Science Limited and Steriscience Specialties Private Limited and Stelis Biopharma Limited and their respective shareholders ('Draft Scheme') pursuant to Section 230 to 232 read with other applicable provisions of the Companies Act, 2013.

Ref: SEBI Master Circular no. SEBI/ HO/ CFD/ POD-2/ P/ CIR/ 2023/ 93 dated June 20, 2023 (SEBI Circular)

This has reference to the captioned application filed by the Company on September 28, 2023, and subsequently hosting of the Draft Scheme related documents on BSE Website on October 5, 2023.

In terms of the SEBI Circular, Company is required to submit a Complaints Report on the Draft Scheme within 7 days of expiry of 21 days from the date of the hosting of the Scheme on website of BSE.

Accordingly, please find enclosed the Complaints Report for the period from October 5, 2023, upto October 26, 2023.

As detailed in the annexed Complaints Report, the Company has received NIL complaints/ comments from the shareholders on the draft Scheme.

You are requested to kindly take the same on record.

Thanks & Regards, For Strides Pharma Science Limited

Manjula Ramamurthy Company Secretary

ICSI Membership No: A30515

Encl. as above







## **Complaints Report**

## Part A

#	Particular	Number	
1	Number of complaints received directly	NIL	
2	Number of complaints forwarded by Stock Exchanges/ SEBI	NIL	
3	Total Number of complaints/comments received (1+2)	NIL	
4	Number of complaints resolved	Not Applicable	
5	Number of complaints pending	Not Applicable	

## Part B

#	Name of complainant	Date of compliant	Status (Resolved/ Pending)		
NOT APPLICABLE					

For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary

Marjula-R.

ICSI Membership No: A30515